Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?

Goossens, Nicolas; Hoshida, Yujin

doi:10.1053/j.gastro.2016.01.006

Cited by 15 publications

(17 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic liver diseases, particularly NAFLD and alcoholic liver disease (ALD), share the pathogenic pathways and mechanisms. [49][50][51][52] There are also consistent similarities in the pathogenesis of complex cholestatic disorders, including primary biliary cholangitis (formerly known as primary biliary cirrhosis) and primary sclerosing cholangitis. [53][54][55] Furthermore, chronic liver damage is associated with conserved pathogenic mechanisms, in particular hepatocyte cell death pathways, inflammatory processes that involve immune response, and fibrogenesis.…”

Section: Shared Molecular Regulatory Pathways Of Chronic Liver Damagementioning

confidence: 95%

Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics

Sookoian

Pirola

2019

Semin Liver Dis

View full text Add to dashboard Cite

Here, the authors review the remarkable genetic discoveries that have illuminated the biology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The authors integrate genes associated with NAFLD and NASH into regulatory pathways to elucidate the disease pathogenesis. They review the evidence for molecular mediators of chronic liver damage, which suggests that convergent pathophenotypes, including inflammation and fibrosis, share common genetic modifiers. They further demonstrate that genes involved in the genetic susceptibility of NAFLD and NASH participate in cross-phenotype associations with diseases of the metabolic syndrome, including type 2 diabetes, obesity, and cardiovascular disease. However, immune-related loci associated with NAFLD and NASH exhibit some level of pleiotropy influencing disparate phenotypes, such as premature birth or sepsis. They finally focus on the translation of current genetic knowledge of NAFLD and NASH toward precision medicine. They provide evidence of genetic findings that can be leveraged to identify therapeutic targets.

show abstract

Section: Shared Molecular Regulatory Pathways Of Chronic Liver Damagementioning

confidence: 95%

Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics

Sookoian

Pirola

2019

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

“…In addition, the magnitude of HCC risk is not yet completely understood in emerging populations, i.e., non-alcoholic fatty liver disease (NAFLD) without cirrhosis and chronic hepatitis C after viral cure especially by direct-acting antivirals [35–39]. More precise individual HCC risk determination will address the heterogeneous HCC risk among patients and enable optimal allocation of limited resources and capability of HCC surveillance to the subset of patients who have higher risk and may benefit more from regular surveillance.…”

Section: From One-size-fits-all To Tailored Hcc Surveillance Strategymentioning

confidence: 99%

Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?

Goossens

Bian

Hoshida

2017

Curr Hepatology Rep

Self Cite

View full text Add to dashboard Cite

Purpose of review Current clinical practice guidelines recommend regular hepatocellular carcinoma (HCC) surveillance with biannual ultrasound with or without serum alpha-fetoprotein uniformly applied to all patients with cirrhosis. However, clinical implementation of this one-size-fits-all strategy has been challenging as evidenced by very low application rate below 20% due to various reasons, including suboptimal performance of the surveillance modalities. Recent findings Newly emerging imaging techniques such as abbreviated MRI (AMRI) and molecular HCC risk biomarkers have increasingly become available for clinical evaluation and implementation. These technologies may have a potential to reshape HCC surveillance by enabling tailored strategies. This would involve performing optimized surveillance tests according to individual HCC risk, and allocating limited medical resources for HCC surveillance based on cost-effectiveness. Summary Tailored HCC surveillance could lead to achievement of precision HCC care and substantial improvement of the current dismal patient prognosis.

show abstract

“…7 This is an area of great scientific and public health relevance. Both forms of liver disease are important risk factors for hepatocellular cancer which is increasing rapidly as a cause of liver-related mortality in those with cirrhosis.…”

mentioning

confidence: 99%